A randomized, multicenter, phase II trial of camrelizumab (Cam) with and without metastasis-directed therapy (MDT) in recurrent/metastatic nasopharyngeal carcinoma (R/M-NPC).

被引：0
|
作者：
Zhang, Xin [1 ]
Yan, Jin [2 ]
Lei, Qianqian
Zhang, Lu
Yang, Jieying
Tan, Sze Huey
Chua, Melvin L. K.
Wang, Ying
Sui, Jiangdong
机构：
[1] Chongqing Univ, Coll Med, Chongqing, Peoples R China
[2] Natl Canc Ctr Singapore, Singapore, Singapore
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 23_SUPPL期
关键词：
D O I：
10.1200/JCO.2024.42.23_suppl.141
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：141 / 141
页数：1
相关论文
共 50 条
  • [11] A single-arm, open-label, multicenter phase II study of camrelizumab in patients with recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) who had progressed on ≥2 lines of chemotherapy: CAPTAIN study
    Zhang, L.
    Yang, Y.
    Chen, X.
    Li, J.
    Pan, J.
    He, X.
    Lin, L.
    Shi, Y.
    Feng, W.
    Xiong, J.
    Yang, K.
    Yu, Q.
    Hu, D.
    Sun, Y.
    Zhang, Q.
    Hu, G.
    Li, P.
    Shen, L.
    Yang, Q.
    Zhang, B.
    ANNALS OF ONCOLOGY, 2020, 31 : S659 - S659
  • [12] A single-arm, open-label, multicenter phase II study of camrelizumab in patients with recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) who had progressed on θ2 lines of chemotherapy: CAPTAIN study
    Zhang, L.
    Yang, Y.
    Chen, X.
    Li, J.
    Pan, J.
    He, X.
    Lin, L.
    Shi, Y.
    Feng, W.
    Xiong, J.
    Yang, K.
    Yu, Q.
    Hu, D.
    Sun, Y.
    Zhang, Q.
    Hu, G.
    Li, P.
    Shen, L.
    Yang, Q.
    Zhang, B.
    ANNALS OF ONCOLOGY, 2020, 31 : S1348 - S1349
  • [13] First-line paclitaxel plus carboplatin with/without bevacizumab in recurrent or metastatic nasopharyngeal carcinoma: A multicenter, randomized, open-label, phase II trial
    Zhang, L.
    Huang, Y.
    Yang, Y.
    Ma, S.
    Lin, X.
    Lin, L.
    Zhou, T.
    Deng, Y.
    Zhang, C.
    Ding, X.
    Wang, S.
    Wang, R.
    Feng, G.
    Chen, Y.
    Xu, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [14] Efficacy and safety of camrelizumab combined with apatinib in previously treated recurrent or metastatic nasopharyngeal carcinoma: A phase II clinical trial.
    Tang, Lin-Quan
    Jia, Guo-Dong
    Lv, Xiao-Fei
    Xie, Siyi
    Chen, Yu
    Li, Ji-Bin
    Li, Xiao Yun
    Zhu, Manyi
    Liu, Sai Lan
    Liu, LiTing
    Sun, Xue-Song
    Guo, Shanshan
    Luo, Dong-Hua
    Chen, Qiu-Yan
    Mai, Hai-Qiang
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [15] Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial
    Karel Decaestecker
    Gert De Meerleer
    Filip Ameye
    Valerie Fonteyne
    Bieke Lambert
    Steven Joniau
    Louke Delrue
    Ignace Billiet
    Wim Duthoy
    Sarah Junius
    Wouter Huysse
    Nicolaas Lumen
    Piet Ost
    BMC Cancer, 14
  • [16] A phase II clinical trial of camrelizumab combined with cetuximab and chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)
    Ji, D.
    Sang, Y.
    Liu, X.
    Guo, Y.
    Yang, Y.
    Chen, G.
    Dong, S.
    Wang, Y.
    He, X.
    Ying, H.
    Lu, X.
    Wang, Y.
    Hu, C.
    Ji, Q.
    ANNALS OF ONCOLOGY, 2024, 35 : S626 - S626
  • [17] Gemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma in Taiwan: a multicenter prospective Phase II trial
    Hsieh, Jason Chia-Hsun
    Hsu, Cheng-Lung
    Ng, Shu-Hang
    Wang, Cheng-Hsu
    Lee, Kuan-Der
    Lu, Chang-Hsien
    Chang, Yi-Fang
    Hsieh, Ruey-Kuen
    Yeh, Kun-Huei
    Hsiao, Chi-Huang
    Chen, Sheng-Yu
    Shiau, Cheng-Ying
    Wang, Hung-Ming
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2015, 45 (09) : 819 - 827
  • [18] Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial
    Decaestecker, Karel
    De Meerleer, Gert
    Ameye, Filip
    Fonteyne, Valerie
    Lambert, Bieke
    Joniau, Steven
    Delrue, Louke
    Billiet, Ignace
    Duthoy, Wim
    Junius, Sarah
    Huysse, Wouter
    Lumen, Nicolaas
    Ost, Piet
    BMC CANCER, 2014, 14
  • [19] Addition of metastasis-directed therapy to standard-of-care systemic therapy for oligometastatic pancreatic ductal adenocarcinoma (EXTEND): Results of a multicenter, randomized phase II trial.
    Ludmir, Ethan B.
    Sherry, Alexander Dean
    Fellman, Bryan M.
    Liu, Suyu
    Bathala, Tharakeswara
    Haymaker, Cara L.
    Medina-Rosales, Marina N.
    Holliday, Emma B.
    Smith, Grace L.
    Lee, Michael Sangmin
    Zhao, Dan
    Smaglo, Brandon George
    Taniguchi, Cullen M.
    Koay, Eugene Jon
    Katz, Matthew H. G.
    Wolff, Robert A.
    Das, Prajnan
    Pant, Shubham
    Koong, Albert C.
    Tang, Chad
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 603 - 603
  • [20] Adding Metastasis-Directed Therapy to Standard-of-Care Systemic Therapy for Oligometastatic Breast Cancer (EXTEND): A Multicenter, Randomized Phase 2 Trial
    Reddy, Jay P.
    Sherry, Alexander D.
    Fellman, Bryan
    Liu, Suyu
    Bathala, Tharakeswara
    Haymaker, Cara
    Cohen, Lorenzo
    Smith, Benjamin D.
    Ramirez, David
    Shaitelman, Simona F.
    Chun, Stephen G.
    Medina-Rosales, Marina
    Teshome, Mediget
    Brewster, Abenaa
    Barcenas, Carlos H.
    Reuben, Alexandre
    Ghia, Amol J.
    Ludmir, Ethan B.
    Weed, Daniel
    Shah, Shalin J.
    Mitchell, Melissa P.
    Woodward, Wendy A.
    Gomez, Daniel R.
    Tang, Chad
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2025, 121 (04): : 885 - 893
12345